Hormone therapy based on tumor gene test results
Part of Cancer, Skin clinical trials.
This trial studies whether younger, premenopausal women with early-stage, hormone-sensitive breast cancer can safely use hormone therapy alone after surgery, based on their tumor's gene activity score (Oncotype DX). It aims to find the best treatment approach based on your cancer's biology.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or younger when first diagnosed with breast cancer.
- You have not gone through menopause yet (you still have periods or your FSH level is low).
- Your breast cancer was removed by surgery between 2012 and 2021 with the goal of curing it.
- Your tumor is small to moderate size (pT1 to pT3) and has spread to up to 1 lymph node (pN0 or pN1).
- Your cancer cells have hormone receptors (ER and/or PR positive) and are not HER2-positive.
- You have had an Oncotype DX test with a recurrence score of 11–25 if no nodes involved, or 25 or less if 1 node involved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.